Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDMA prodrug
- Development stage
- Preclinical
- Lead developer
- Terran Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MDMA prodrug is a preclinical-stage small molecule prodrug designed by Terran Biosciences to be a long-acting form of 3,4-methylenedioxymethamphetamine (MDMA). Engineered with a side chain modification, the prodrug is designed to improve pharmacokinetics, extend the duration of action, and potentially eliminate the need for booster dosing (redosing) during MDMA-assisted psychotherapy. In animal models, the prodrug has demonstrated a longer duration of action with a reliable pharmacokinetic profile. It is intended for the treatment of neuropsychiatric and psychiatric indications, such as post-traumatic stress disorder (PTSD) and major depressive disorder (MDD).
- Other names
- long-acting MDMAlong-acting MDMA prodrugMDMA prodrugsmidomafetamine prodrug
02
Targets
NET (Norepinephrine Transporter)HTR2C (5-hydroxytryptamine 2C receptor)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on MDMA prodrug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDMA prodrug.